People: Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

16.53USD
1 Aug 2013
Price Change (% chg)

$-0.73 (-4.23%)
Prev Close
$17.26
Open
$16.78
Day's High
$16.95
Day's Low
$16.48
Volume
233,326
Avg. Vol
137,075
52-wk High
$18.02
52-wk Low
$10.05

Search Stocks

Summary

Name Age Since Current Position

James Sulat

63 2008 Independent Chairman of the Board

Craig Wheeler

52 2006 President, Chief Executive Officer, Director

Richard Shea

60 2007 Chief Financial Officer, Senior Vice President

Ganesh Kaundinya

45 2007 Senior Vice President - Research, Chief Scientific Officer

Bruce Leicher

56 2008 Senior Vice President, General Counsel, Secretary

John Bishop

50 2006 Senior Vice President - Pharmaceutical Sciences

James Roach

52 2008 Senior Vice President - Development, Chief Medical Officer

John Clarke

59 2002 Independent Director

Bruce Downey

64 2009 Independent Director

Marsha Fanucci

59 2005 Independent Director

Peter Hutt

78 2001 Independent Director

Thomas Koestler

61 2011 Independent Director

Bennett Shapiro

72 2003 Independent Director

Elizabeth Stoner

62 2007 Independent Director

Biographies

Name Description

James Sulat

Mr. James R. Sulat is an Independent Chairman of the Board of Momenta Pharmaceuticals Inc since December 2008. Since September 2009, Mr. Sulat has served as the Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., a biopharmaceutical company. Prior to that, he served as the Chief Financial Officer of Memory Pharmaceuticals Corp., a biopharmaceutical company, from February 2008 through September 2008, and previously served as Memory Pharmaceuticals' President and Chief Executive Officer from May 2005 through February 2008 and as a member of the board of directors of Memory Pharmaceuticals from May 2005 through January 2009. Mr. Sulat serves as a director of Maxygen, Inc. and Intercell AG. Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.

Craig Wheeler

Mr. Craig A. Wheeler is President, Chief Executive Officer, Director of Momenta Pharmaceuticals Inc. Prior to joining Momenta, Mr. Wheeler served as President of Chiron Biopharmaceuticals, a division of Chiron Corporation, a biotechnology company, from August 2001 until June 2006. Mr. Wheeler has been a member of the board of directors of Avanir Pharmaceuticals, Inc. since September 2005 and has served as chairman of the board since May 2007. Mr. Wheeler received B.S. and M.S. degrees in chemical engineering from Cornell University and an M.B.A. degree from the Wharton School of the University of Pennsylvania.

Richard Shea

Mr. Richard P. Shea is the Chief Financial Officer, Senior Vice President of Momenta Pharmaceuticals Inc since July 2007. From October 2003 through July 2007, he served as our Vice President and Chief Financial Officer. From April 2002 to April 2003, Mr. Shea served as Chief Operating Officer for Variagenics, Inc., a pharmacogenomics company. From March 2000 to April 2002, Mr. Shea served as Variagenics, Inc.'s Chief Financial Officer and from February 1999 to March 2000, he served as its Vice President, Finance and Administration. Mr. Shea is a CPA and received his A.B. from Princeton University and his M.B.A. from Boston University.

Ganesh Kaundinya

Dr. Ganesh Venkataraman Kaundinya, Ph.D., is Senior Vice President - Research, Chief Scientific Officer of Momenta Pharmaceuticals Inc. He is a co-founder of company and has been Chief Scientific Officer since September 2007 and Senior Vice President, Research since April 2005. From January 2002 through April 2005, he served as Vice President, Technology. Dr. Kaundinya received his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Bruce Leicher

Mr. Bruce A. Leicher is Senior Vice President, General Counsel, Secretary of Momenta Pharmaceuticals Inc. He has been our Senior Vice President and General Counsel since July 2008 and Secretary since September 2008. From December 2006 to July 2008, Mr. Leicher served as Senior Vice President, General Counsel and Secretary at Altus Pharmaceuticals Inc., a biopharmaceutical company. From December 2005 to December 2006, he served as Vice President, General Counsel and Secretary at Antigenics Inc., a biotechnology company. Mr. Leicher received his B.A. from the University of Rochester and his J.D. from Georgetown University Law Center. After earning his law degree, Mr. Leicher served as a law clerk to the Honorable Thomas F. Hogan, U.S. District Court Judge for the District of Columbia.

John Bishop

Dr. John E. Bishop, Ph.D. is Senior Vice President - Pharmaceutical Sciences of Momenta Pharmaceuticals Inc since December 2006. He served as Vice President, Pharmaceutical Sciences and Manufacturing from November 2004 to December 2006. From August 2000 to October 2004, Dr. Bishop served as Director and Head of Process Development (Chemical and Biologics) at Millennium Pharmaceuticals, Inc. During that period, he also led the Chemistry, Manufacturing and Controls (CMC) team for VelcadeĀ®, a type of cancer medicine. Dr. Bishop received his B.S. magna cum laude in Chemistry and German from Tufts University, his Ph.D. in Organic Chemistry from UC Berkeley and his M.B.A. from Northeastern University.

James Roach

Dr. James M. Roach, M.D., is the Senior Vice President - Development, Chief Medical Officer of Momenta Pharmaceuticals Inc since February 2008. From January 2006 to February 2008, Dr. Roach served as Senior Vice President, Medical Affairs at Sepracor Inc., a pharmaceutical company, where he also served as Vice President, Medical Affairs from July 2002 to December 2005 and as Executive Medical Director, Medical Affairs from January 2002 to June 2002. Dr. Roach is board certified in Internal Medicine, Pulmonary Disease, and Critical Care Medicine and is an Assistant Clinical Professor of Medicine at Harvard Medical School and an Associate Physician at Brigham and Women's Hospital. Dr. Roach received his B.A. in biology and philosophy from the College of the Holy Cross and his M.D. from Georgetown University School of Medicine. He completed his residency in Internal Medicine and fellowship in Pulmonary and Critical Care Medicine at the Walter Reed Army Medical Center in Washington, D.C.

John Clarke

Mr. John K. Clarke is an Independent Director of Momenta Pharmaceuticals Inc since April 2002. Mr. Clarke founded Cardinal Partners, a venture capital firm, in 1997, and has served as its Managing General Partner since its founding. He has founded and served as interim Chief Executive Officer of a number of portfolio companies, including Alkermes, Inc., Arris Pharmaceuticals, Inc., Cubist Pharmaceuticals, Inc. and the DNX Corporation. Mr. Clarke is chairman of the board of directors of Alnylam Pharmaceuticals, Inc. and serves as a member of the board of directors of Verastem, Inc. as well as a number of privately-held healthcare companies. During the last five years, Mr. Clarke also served as a member of the board of directors of Cubist Pharmaceuticals, Inc., Sirtris Pharmaceuticals and Visicu, Inc. He received his B.A. in Biology and Economics from Harvard College and his M.B.A. from the Wharton School of the University of Pennsylvania.

Bruce Downey

Mr. Bruce L. Downey is an Independent Director of Momenta Pharmaceuticals Inc. Mr. Downey has served as a Partner at NewSpring Capital, a venture capital firm, since April 2009. Previously, Mr. Downey was Chairman and Chief Executive Officer of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company that operated in more than 30 countries worldwide and was acquired by Teva Pharmaceuticals in 2008. Mr. Downey joined Barr Pharmaceuticals, Inc. in 1993 and was appointed Chairman of the Board and Chief Executive Officer in 1994. Mr. Downey is a member of the board of directors of Cardinal Health, Inc. as well as privately held companies. Mr. Downey graduated with honors from Miami University in 1969 and received his law degree cum laude from Ohio State.

Marsha Fanucci

Ms. Marsha H. Fanucci is an Independent Director of Momenta Pharmaceuticals Inc since March 2005. Ms. Fanucci served as Senior Vice President and Chief Financial Officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company, from July 2004 through January 2009, where she was responsible for corporate strategy, treasury, financial planning and reporting and operations. While at Millennium since 2000, she also served as Vice President, Finance and Corporate Strategy and Vice President, Corporate Development. (Millennium was acquired by Takeda Pharmaceutical Company Limited in May 2008 and is now Millennium: The Takeda Oncology Company). Ms. Fanucci is a member of the board of directors of Alnylam Pharmaceuticals, Inc. and Ironwood Pharmaceuticals, Inc. She received her B.S. in Pharmacy from West Virginia University and her M.B.A. from Northeastern University.

Peter Hutt

Mr. Peter Barton Hutt, LL.B., L.L.M. is an Independent Director of Momenta Pharmaceuticals Inc since June 2001.Mr. Hutt is a senior counsel at the law firm of Covington & Burling LLP and has been an attorney with that firm beginning in 1960. He served as Chief Counsel for the Food and Drug Administration from 1971 through 1975. Mr. Hutt is a member of the Institute of Medicine of the National Academy of Sciences and teaches a course on Food and Drug Law each Winter Term at Harvard Law School. He co-authored the casebook used to teach Food and Drug Law and has published numerous papers on the subject. Mr. Hutt is a member of the board of directors of Ista Pharmaceuticals, Inc., Xoma Ltd., and several privately-held life sciences companies. During the last five years, Mr. Hutt also served as a member of the board of directors of Celera Genomics, CV Therapeutics, Inc., Favrille, Inc. and Introgen Therapeutics, Inc. Mr. Hutt received his B.A., magna cum laude, from Yale University, his L.L.B. from Harvard University and his L.L.M. from New York University.

Thomas Koestler

Dr. Thomas P. Koestler, Ph.D. is an Independent Director of Momenta Pharmaceuticals, Inc. Since February 2010, Dr. Koestler has served as Executive Director-Healthcare at Vatera Healthcare Partners, a venture capital company. Prior to joining Vatera Healthcare Partners, Dr. Koestler was Executive Vice President of Schering-Plough Corporation, a pharmaceutical company, and President of Schering-Plough Research Institute, the pharmaceutical research and development arm of Schering-Plough Corporation, which he joined in 2003. Dr. Koestler has also held senior positions at Pharmacia Corporation, Novartis AG, Ortho-McNeil and Bristol-Myers Squibb. Dr. Koestler is also a member of the board of directors of Novo Nordisk A/S and a number of privately-held companies. Dr. Koestler holds a BS degree in biology and genetics from Daemen College and a Ph.D. from the State University of New York, where he studied medicine and pathology.

Bennett Shapiro

Dr. Bennett M. Shapiro, M.D., is an Independent Director of Momenta Pharmaceuticals Inc since May 2003. Since June 2006, he has served as a Senior Partner at PureTech Ventures, a venture capital firm, and since August 2003 he has served as a private consultant providing advice to executives. From September 1990 to July 2003, Dr. Shapiro served as an Executive Vice President of Merck & Co., Inc., a research-based pharmaceutical company. Dr. Shapiro is the former head of Worldwide Licensing and External Research at Merck; prior to that he served as the head of Basic and Preclinical Research at Merck and as Chairman of the Biochemistry department at the University of Washington. Dr. Shapiro serves on the board of a number of privately-held biopharmaceutical companies. During the last five years, Dr. Shapiro also served as a member of the board of directors of Celera Genomics. Dr. Shapiro received his B.S. in Chemistry from Dickinson College and his M.D. from Jefferson Medical College.

Elizabeth Stoner

Dr. Elizabeth Stoner, M.D., is an Independent Director of Momenta Pharmaceuticals Inc. Since March 2010, Dr. Stoner has been the Chief Development Officer at Rhythm Pharmaceuticals, a biotechnology company. Since October 2007, Dr. Stoner has served as a Managing Director at MPM Capital, a healthcare venture capital firm. Prior to joining MPM Capital, Dr. Stoner had a 22-year career at Merck Research Laboratories. At the time of her retirement from Merck, Dr. Stoner was Senior Vice President of Global Clinical Development Operations with responsibility for the company's clinical development activities in more than 40 countries. Prior to her position at Merck, she was an Assistant Professor of Pediatrics at Cornell University Medical College. Dr. Stoner serves on the board of a privately-held biopharmaceutical company. During the last five years, Dr. Stoner served on the board of Metabasis Therapeutics, Inc., a biopharmaceutical company. Dr. Stoner received her B.S. in Chemistry from Ottawa University, KS, her M.S. in Chemistry from the State University of New York at Stony Brook, and her M.D. from Albert Einstein College of Medicine.

Basic Compensation

Name Fiscal Year Total

James Sulat

--

Craig Wheeler

4,990,820

Richard Shea

1,458,660

Ganesh Kaundinya

1,522,350

Bruce Leicher

1,519,090

John Bishop

651,043

James Roach

1,500,170

John Clarke

--

Bruce Downey

--

Marsha Fanucci

--

Peter Hutt

--

Thomas Koestler

--

Bennett Shapiro

--

Elizabeth Stoner

--
As Of 30 Dec 2011

Options Compensation

Name Options Value

James Sulat

0 0

Craig Wheeler

23,000 287,437

Richard Shea

132,850 2,722,490

Ganesh Kaundinya

127,400 2,218,549

Bruce Leicher

0 0

John Bishop

107,875 1,303,888

James Roach

0 0

John Clarke

0 0

Bruce Downey

0 0

Marsha Fanucci

0 0

Peter Hutt

0 0

Thomas Koestler

0 0

Bennett Shapiro

0 0

Elizabeth Stoner

0 0
Search Stocks